medigraphic.com
ISSN 1561-2988 (Print)

2015, Number 4

<< Back Next >>

Rev Cubana Farm 2015; 49 (4)

Abacavir, an updated review on its properties and applications

Rabeiro MCL, Martinez RA, Gravier HR, Bermudez AY, Gil VL

Language: Spanish
References: 58
Page: 751-764
PDF size: 174.02 Kb.


ABSTRACT

The National Strategic Plan for the Prevention and Control of the IST/HIV/ aids, 2014-2018 in Cuba establishes a group of actions such as the standardization and optimization of antiretroviral therapy schedules, adaptation of the beginning of the treatment to the recent recommendations of the World Health Organization, the improvement of the quality of care, the adherence to and the reduction of the cost of medications. For the purpose of complying with these tasks, it is anticipated to introduce in the basic drug listing some Cuban generic antiretroviral drugs to increase the possible combinations of the Highly Active Antiretroviral Therapy available for patients who live with the human immunodeficiency virus and to reduce imports. An exhaustive literature review was made for the update of the medical and scientific community knowledge. This article analyzed the main characteristics of abacavir such as chemical-physical properties of the active principle, their commercial presentations, mechanism of action, pharmacokinetics and resistance, adverse reactions and interactions, therapeutic applications, dosages, dose adjustments and safety at pregnancy. To this end, a total of 58 articles were consulted including literature reviews, original papers, technical records, books, lectures and reports. Abacavir is a relatively new antiretroviral, widely recommended by treatment guidelines on account of its proven effectiveness.


REFERENCES

  1. Delgado R. Características virológicas del VIH. Enferm Infecc Microbiol Clin. 2011;29(1):58-65.

  2. ONUSIDA. Informe sobre la epidemia mundial de sida. Génova: ONU. 2013.

  3. AIDSinfo. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 2013. [access december 2014]. Available from: http://aidsinfo.nih.gov/guidelines2013

  4. Pérez J. Approaches to the management of HIV/AIDS in Cuba: case study (Perspectives and practice in antirretroviral treatment). WHO. 2004.

  5. Aragones C, Sánchez L, Campos J, Pérez J. Antiretroviral therapy adherence in persons with HIV/AIDS in Cuba. MEDICC Rev. 2011;13(2):17-23.

  6. Colectivo de autores. Informe estadísticas MINSAP. Reunión Técnica de sida. 2013-2014.

  7. Pérez L, Alemán J, Correa C, Pérez J, Fonseca C, Aragonés C, et al. Molecular epidemiology of antiretroviral resistance in therapy-experienced HIV-1 patients in Cuba (2009). Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010; Glasgow, UK.

  8. Kouri V, Alemán Y, Pérez L, Pérez J, Fonseca C, Correa C, et al. High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba. Journal of Clinical Virology 2012 7-11 November 2010; 55:348– 55.

  9. MINSAP. Plan Estratégico Nacional ITS-VIH/sida 2014-2018. La Habana; 2013.

  10. Ribera E. Características de los fármacos antirretrovirales. Enferm Infecc Microbiol Clin. 2011;29(5):362-91.

  11. McDowell J, Lou Y, Symonds W. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000;44:2061-7.

  12. Información procedente de las fichas técnicas americanas de los productos (FDA and First Data Bank, Inc) [access 5 Dic 2010]. Available from: http://www.rxlist.com/drugs/alphaa.htm

  13. MINSAP. Sidatrat. 2014 [Consultado 13 Abril 2015]. Disponible en: http://www.informatica2013.sld.cu/index.php/informaticasalud/2013/paper/viewFil e/225/191

  14. Montvale N. Physicians' Desk Reference. Medical Economics Co. 55th ed. 2001.

  15. PubChem. 2D Structure [access 24 April 2015]. Available from: http://pubchem.ncbi.nlm.nih.gov/compound/441384#section=Top

  16. Colectivo de autores. Guía de manejo antirretroviral de las personas con VIH 5ed. México: Censida; 2012.

  17. Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli S. Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food. J Acquir Immune Defic Syndr. 2014;66(4):393-8.

  18. Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-18.

  19. Greig S, Deeks E. Abacavir/Dolutegravir/Lamivudine Single-Tablet Regimen: A Review of Its Use in HIV-1 Infection. Drugs. 2015;75(5):561.

  20. Tabla de especialidades farmacéuticas comercializadas que pueden ser utilizadas para la administración por SE, con los excipientes y características fisicoquímicas recogidas en la bibliografía. Nutr Hosp. 2006;21(4):11-128.

  21. Bethesda M. American Society of Health-System Pharmacists. In: McEvoy G, editor. American Hospital Formulary Service-Drug Information; 2003.

  22. Vademecum. Abacavir [access 14 April 2015]. Available from: http://www.iqb.es/cbasicas/farma/farma04/a012.htm

  23. Ficha técnica Ziagen 300 mg [access 13 April 2015]. Available from: www.ema.europa.eu/docs/es_ES

  24. Fichas técnicas europeas de los antirretrovirales [access 3 Nov 2010]. Available from: http://www.ema.europa.eu

  25. Martínez J. Farmacocinética y farmacodinámica de los principales antirretrovirales. Aids Caber J. 2003;6(2):116-23.

  26. McDowell J, Chittick G, Ravitch J. Pharmacokinetics of [14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999;43:2855-61.

  27. Gilliam B, Sajadi M, Amoroso A, Davis C, Cleghorn F, Redfield R. Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population. AIDS Patient Care STDS. 2007;21(4):240-6.

  28. Dando T, Scott L. Abacavir plus lamivudine. A review of their combined use in the management of HIV infection. Drugs. 2005;65:28-302.

  29. Hewitt R. Abacavir Hypersensitivity Reaction. Clinical Infectious Diseases. 2002;34:1137-42.

  30. Panel de Expertos de Gesida. Plan Nacional sobre el Sida. Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010). Enferm Infecc Microbiol Clin. 2010;28(362):1–91.

  31. Tangamornsuksan W, Lohitnavy O, Kongkaew C, Chaiyakunapruk N, Reisfeld B, Scholfield N. Association of HLA-B*5701 Genotypes and Abacavir-Induced Hypersensitivity Reaction: A Systematic Review and Meta-Analysis. J Pharm Pharm Sci. 2015;18(1):68-76.

  32. Crovella S, Biller L, Santos S, Salustiano A, Brandao L, Guimaraes R, et al. Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil. Clinics. 2011;66(8).

  33. Mallal S, Phillips E, Carosi G, Molina J, Workman C, Tomazic J. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-79.

  34. Martin M, Kroetz D. Abacavir Pharmacogenetics - From Initial Reports to Standard of Care. Pharmacotherapy. 2013;33(7):765-75.

  35. Hess D, Rieder M. The role of reactive metabolites in immunemediated adverse drug reactions. Ann Pharmacother. 1997;31:1378–87.

  36. Clay P, Rathbun R, Slater L. Management protocol for abacavirrelated hypersensitivity reaction. Ann Pharmacother. 2000;34:247-9.

  37. Sabin C, Worm S. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet. 2008;371(1417-1126).

  38. El-Sadr W, Lundgren J. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ countguided interruption of antiretroviral treatment. N Engl J Med. 2006; 355:2283-96.

  39. Obel N, Farkas D, Kronborg G, Larsen C, Pedersen G, Riis A, et al. Abacavir and Risk of Myocardial Infarction in HIV-infected Patients on Highly Active Antiretroviral Therapy: A Population-based Nationwide Cohort Study HIV Medicine. Blackwell Publishing. 2010;11(2):130-6.

  40. Li R, Yang C, Chan S, Hoi M, Lee S, Kwan Y. Relaxation effect of abacavir on rat basilar arteries. PLoS One. 2015;10(4). Pubmed Central PMCID:4390379.

  41. Cutrell A, Hernandez J, Yeo J. Is abacavir-containing combination antiretroviral therapy associated with myocardial infarction? No association identified in pooled summary of 54 clinical trials. 17th International AIDS Conference; Mexico DF; 2008.

  42. Rakesh D, Stephen G. Severe metabolic acidosis and Fanconi syndrome during stavudine and abacavir therapy in a resource-limited setting. Brazilian Journal of Infectious Diseases. 2012;16(6).

  43. McDowell J, Chittick G, Stevens C, Edwards K, Stein D. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virusinfected adults. Antimicrob Agents Chemother. 2000;44(6):1686-90.

  44. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV‐HIV International Panel. AIDS. 2007;21(9):1073-89.

  45. Staszewski S. Coming therapies: abacavir. Int J Clin Pract 1999;103:35-8.

  46. Staszewski S, Keiser P, Montaner J. Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults: a randomized equivalence trial. JAMA. 2001;285:1155-63.

  47. Kost R, Hurley A, Zhang L. Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1-infected patients. J Acquir Immune Defic Syndr. 2001;26:332-9.

  48. Katlama C, Clotet B, Plettenberg A. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, doubleblind, trial: CNA3002 European Study Team. AIDS. 2000;14:781-9.

  49. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia C, Brand J. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39(7):1038-46.

  50. Moyle G, DeJesus E, Cahn P, Castillo S, Zhao H, Gordon D. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38(4):417-25.

  51. Podzamczer D, Ferrer E, Sanchez P, Gatell J, Crespo M, Fisac C. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96- week results of a randomized study. J Acquir Immune Defic Syndr. 2007;44(2):139-47.

  52. Smith K, Fine D, Patel P. Efficacy and safety of abacavir/lamivudine compared to enofovir/emtricitabine in combination with once‐daily lopinavir/ritonavir through 48 weeks in the HEAT Study. 15th Conference on Retroviruses and Opportunistic Infections; Boston, Massachusetts; 2008.

  53. Smith K, Fine D, Patel P. Similarity in efficacy and safety of abacavir/lamivudine compared to tenofovir/emtricitabine in combination with QD lopinavir/ritonavir (LPV/r) over 96 weeks in the HEAT study. 17th International AIDS Conference; Mexico DF: OMS; 2008.

  54. Sax P, Tierney C, Collier A. ACTG 5202: shorter time to virologic failure with ABC/3TC than TDF/FTC in treatment‐naïve subjects with HIV RNA >100,000. 17th International AIDS Conference; Mexico DF: OMS; 2008.

  55. Hoogewerf M, Regez R, Schouten W, Weigel H, Frissen P, Brinkman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet. 2003;362(9400):1979-80.

  56. Moyle G, Sabin C, Cartledge J, Johnson M, Wilkins E, Churchill D. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20(16):2043-50.

  57. Riddler S, Haubrich R, DiRienzo A, Peeples L, Powderly W, Klingman K. Classsparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095-106.

  58. Negredo E, Diez-Pérez A, Bonjoch A, Domingo P, Pérez-Álvarez N, Gutierrez M. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. J Antimicrob Chemother. 2015. Pubmed Central PMCID: 25769303.




2020     |     www.medigraphic.com